Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Inolitazone (RS5444) 是一种高亲和力PPARγ激动剂。在体外,Inotazone 显示生长抑制的IC50约为0.8 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 978 | 现货 | ||
5 mg | ¥ 2,670 | 现货 | ||
10 mg | ¥ 3,980 | 现货 | ||
25 mg | ¥ 6,360 | 现货 | ||
50 mg | ¥ 8,720 | 现货 | ||
100 mg | ¥ 11,700 | 现货 | ||
500 mg | ¥ 23,500 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 3,380 | 现货 |
产品描述 | Inolitazone (RS5444) a high-affinity PPARγ agonist. Inolitazone exhibits IC50 for growth inhibition is ~0.8 nM in vitro. |
体外活性 | Inolitazone (10 nM) inhibits the growth of DRO cells through a PPARγ-dependent mechanism[1]. Inolitazone upregulates the cell cycle kinase inhibitor, p21WAF1/CIP1. Inolitazone (10 nM) activates PPARγ:RXRα-dependent transcription utilizing a PPRE response element fused to a luciferase reporter gene (PPRE3-tk-luc). Inolitazone specifically activates PPARγ, but not PPARα or PPARδ. Inolitazone (10 nM) following transient transfection with the appropriate PPAR isoform (γ, α, or δ) and PPAR response element linked to a luciferase reporter in RIE rat small intestinal cell line, which does not express PPARs, yields increased luciferase activity only in the presence of PPARγ and PPRE3-tk-luc[2]. |
体内活性 | In athymic nude mice prior to DRO tumor cell implantation, Inolitazone inhibits tumor growth in a dose responsive fashion. 0.025% Inolitazone inhibits growth on day 32 by 94.4%. In the 0.0025% treatment group, tumor growth is inhibited by 62.3% while the 0.00025% dose demonstrated no growth inhibitory activity as compared to control. Inolitazone treated animals demonstrate tumor growth inhibition of 68.9% in DRO tumors and 48.3% in ARO tumors on day 35. Inolitazone plus Paclitaxel demonstrate additive antiproliferative activity in cell culture and minimal ATC tumor growth[1]. |
别名 | RS5444, Efatutazone, CS-7017, 伊诺他酮 |
分子量 | 502.58 |
分子式 | C27H26N4O4S |
CAS No. | 223132-37-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (109.43 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.9897 mL | 9.9487 mL | 19.8973 mL | 49.7433 mL |
5 mM | 0.3979 mL | 1.9897 mL | 3.9795 mL | 9.9487 mL | |
10 mM | 0.199 mL | 0.9949 mL | 1.9897 mL | 4.9743 mL | |
20 mM | 0.0995 mL | 0.4974 mL | 0.9949 mL | 2.4872 mL | |
50 mM | 0.0398 mL | 0.199 mL | 0.3979 mL | 0.9949 mL | |
100 mM | 0.0199 mL | 0.0995 mL | 0.199 mL | 0.4974 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Inolitazone 223132-37-4 DNA Damage/DNA Repair Metabolism PPAR Peroxisome proliferator-activated receptors RS5444 RS 5444 Efatutazone RS-5444 CS 7017 CS-7017 Inhibitor 伊诺他酮 inhibit CS7017 inhibitor